[1]Blobel CP, Wolfsberg TG, Turck CW, Myles DG, Primakoff P, White JM. A potential fusion peptide and an integrin ligand domain in a protein active in sperm-egg fusion.
Nature. 1992;356(6366):248-252. doi:10.1038/356248a0.
[2]Lichtenthaler SF, Lemberg MK, Fluhrer R. Proteolytic ectodomain shedding of membrane proteins in mammals—hardware, concepts, and recent developments. The EMBO
Journal. 2018;37(15):e99456. doi:10.15252/embj.201899456.
[3]Cho C. Testicular and epididymal ADAMs: expression and function during fertilization. Nat Rev Urol. 2012;9(10):550-560. doi:10.1038/nrurol.2012.167.
[4]Weber S, Saftig P. Ectodomain shedding and ADAMs in development. Development. 2012;139(20):3693-3709. doi:10.1242/dev.076398.
[5]Mullooly M, McGowan PM, Crown J, Duffy MJ. The ADAMs family of proteases as targets for the treatment of cancer. Cancer Biol Ther. 2016;17(8):870-880. doi:10.1080
/15384047.2016.1177684.
[6]Stöcker W, Grams F, Baumann U, et al. The metzincins--topological and sequential relations between the astacins, adamalysins, serralysins, and matrixins (collagenases)
define a superfamily of zinc-peptidases. Protein Sci. 1995;4(5):823-840. doi:10.1002/pro.5560040502.
2024.12 | 015
[7]Sagane K, Ohya Y, Hasegawa Y, Tanaka I. Metalloproteinase-like, disintegrin-like, cysteine-rich proteins MDC2 and MDC3: novel human cellular disintegrins highly expressed in the brain. Biochemical Journal. 1998;334(1):93-98. doi:10.1042/bj3340093.
[8]Sagane K, Hayakawa K, Kai J, et al. Ataxia and peripheral nerve hypomyelination in ADAM22-deficient mice. BMC Neurosci. 2005;6(1):33. doi:10.1186/1471-2202-6-33.
[9]Fukata Y, Adesnik H, Iwanaga T, Bredt DS, Nicoll RA, Fukata M. Epilepsy-Related Ligand/Receptor Complex LGI1 and ADAM22 Regulate Synaptic Transmission. Science. 2006;313(5794):1792-1795. doi:10.1126/science.1129947.
[10]Lovero KL, Fukata Y, Granger AJ, Fukata M, Nicoll RA. The LGI1–ADAM22 protein complex directs synapse maturation through regulation of PSD-95 function. Proc Natl Acad Sci USA. 2015;112(30). doi:10.1073/pnas.1511910112.
[11]Fukata Y, Lovero KL, Iwanaga T, et al. Disruption of LGI1-linked synaptic complex causes abnormal synaptic transmission and epilepsy. Proc Natl Acad Sci U S A. 2010;107(8):3799-3804. doi:10.1073/pnas.0914537107.
[12]Dazzo E, Leonardi E, Belluzzi E, et al. Secretion-Positive LGI1 Mutations Linked to Lateral Temporal Epilepsy Impair Binding to ADAM22 and ADAM23 Receptors. PLoS Genet. 2016;12(10):e1006376. doi:10.1371/journal.pgen.1006376.
[13]Yokoi N, Fukata Y, Kase D, et al. Chemical corrector treatment ameliorates increased seizure susceptibility in a mouse model of familial epilepsy. Nat Med. 2015;21(1):19-26. doi:10.1038/nm.3759.
[14]Yamagata A, Miyazaki Y, Yokoi N, et al. Structural basis of epilepsy-related ligand–receptor complex LGI1–ADAM22. Nat Commun. 2018;9(1):1546. doi:10.1038/s41467-018-03947-w.
[15]Özkaynak E, Abello G, Jaegle M, et al. Adam22 Is a Major Neuronal Receptor for Lgi4-Mediated Schwann Cell Signaling. J Neurosci. 2010;30(10):3857-3864. doi:10.1523/JNEUROSCI.6287-09.2010.
[16]Xue S, Maluenda J, Marguet F, et al. Loss-of-Function Mutations in LGI4, a Secreted Ligand Involved in Schwann Cell Myelination, Are Responsible for Arthrogryposis Multiplex Congenita. The American Journal of Human Genetics. 2017;100(4):659-665. doi:10.1016/j.ajhg.2017.02.006.
[17]Horiuchi K, Weskamp G, Lum L, et al. Potential role for ADAM15 in pathological neovascularization in mice. Mol Cell Biol. 2003;23(16):5614-5624. doi:10.1128/MCB.23.16.5614-5624.2003.
[18]Hartmann D, de Strooper B, Serneels L, et al. The disintegrin/metalloprotease ADAM 10 is essential for Notch signalling but not for alpha-secretase activity in fibroblasts. Hum Mol Genet. 2002;11(21):2615-2624. doi:10.1093/hmg/11.21.2615.
[19]Zhou HM, Weskamp G, Chesneau V, et al. Essential role for ADAM19 in cardiovascular morphogenesis. Mol Cell Biol. 2004;24(1):96-104. doi:10.1128/MCB.24.1.96-104.2004.
[20]Kurohara K, Komatsu K, Kurisaki T, et al. Essential roles of Meltrin beta (ADAM19) in heart development. Dev Biol. 2004;267(1):14-28. doi:10.1016/j.ydbio.2003.10.021.
[21]Ohtsu H, Dempsey PJ, Eguchi S. ADAMs as mediators of EGF receptor transactivation by G protein-coupled receptors. Am J Physiol Cell Physiol. 2006;291(1):C1-10. doi:10.1152/ajpcell.00620.2005.
[22]Zhang SM, Jiang L, Zhao X, et al. A disintegrin and metalloprotease 22 accelerates neointima formation by activating ERK signaling. Atherosclerosis. 2019;283:92-99. doi:10.1016/j.atherosclerosis.2019.02.002.
[23]Ren L, Wu C, Yang K, et al. A Disintegrin and Metalloprotease-22 Attenuates Hypertrophic Remodeling in Mice Through Inhibition of the Protein Kinase B Signaling Pathway. J Am Heart Assoc. 2018;7(2):e005696. doi:10.1161/JAHA.117.005696.
[24]Bolger JC. ADAM22 as a Prognostic and Therapeutic Drug Target in the Treatment of Endocrine-Resistant Breast Cancer.
[25]Charmsaz S, Doherty B, Cocchiglia S, et al. ADAM22/LGI1 complex as a new actionable target for breast cancer brain metastasis. BMC Med. 2020;18(1):349. doi:10.1186/s12916-020-01806-4.
[26]McCartan D, Bolger JC, Fagan A, et al. Global characterization of the SRC-1 transcriptome identifies ADAM22 as an ER-independent mediator of endocrine-resistant breast cancer. Cancer Res. 2012;72(1):220-229. doi:10.1158/0008-5472.CAN-11-1976.
[27.Xing B, Lei Z, Wang Z, et al. A disintegrin and metalloproteinase 22 activates integrin β 1 through its disintegrin domain to promote the progression of pituitary adenoma. Neuro-Oncology. 2024;26(1):137-152. doi:10.1093/neuonc/noad148.
[28]Zhu P, Sang Y, Xu H, et al. ADAM22 plays an important role in cell adhesion and spreading with the assistance of 14-3-3. Biochem Biophys Res Commun. 2005;331(4):938-946. doi:10.1016/j.bbrc.2005.03.229.
[29]Murphy G. The ADAMs: signalling scissors in the tumour microenvironment. Nat Rev Cancer. 2008;8(12):929-941. doi:10.1038/nrc2459.
[30]Fridman JS, Caulder E, Hansbury M, et al. Selective inhibition of ADAM metalloproteases as a novel approach for modulating ErbB pathways in cancer. Clin Cancer Res. 2007;13(6):1892-1902. doi:10.1158/1078-0432.CCR-06-2116.
[31]Kenny PA, Bissell MJ. Targeting TACE-dependent EGFR ligand shedding in breast cancer. J Clin Invest. 2007;117(2):337-345. doi:10.1172/JCI29518.
[32]Gabellini N, Masola V. Expression of LGI1 Impairs Proliferation and Survival of HeLa Cells. Int J Cell Biol. 2009;2009:417197. doi:10.1155/2009/417197.
[33]RETRACTION:Increased expression of LGI1 gene triggers growth inhibition and apoptosis of neuroblastoma cells. J Cell Physiol. 2024;239(11):e31411. doi:10.1002/jcp.31411.
[34]Kunapuli P, Kasyapa CS, Hawthorn L, Cowell JK. LGI1, a putative tumor metastasis suppressor gene, controls in vitro invasiveness and expression of matrix metalloproteinases in glioma cells through the ERK1/2 pathway. J Biol Chem. 2004;279(22):23151-23157. doi:10.1074/jbc.M314192200